(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 16833

Total Pages in this Submission

4

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

1	FBE	TAINE IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING I	EFFECTS
'L nd invente	ed by		
Anneli	Torr	onen, Kirsti Jutila, Matti Uusitupa, Ursula Schwab	
	15		
a CONT	INUA	ATION APPLICATION, check appropriate box and supply the requisite information:	
⊠ Cont	inuat	ion Divisional Continuation-in-part (CIP) of prior application No.:	PCT/FI02/00024
Vhich is a	a:		
☐ Cont	inua	ion Divisional Continuation-in-part (CIP) of prior application No.:	
(hich is a			
⊒ Cont	inual	ion Divisional Continuation-in-part (CIP) of prior application No.:	
nclosed	are:		
		Application Elements	* *
1. 🗵	Filir	ng fee as calculated and transmitted as described below	
		ig fee as calculated and transmitted as described below	
	C		*
2. 🛚	Spe	cification having 16 pages and including the following:	
2. 🛚	E-3		
a.		cification having 16 pages and including the following:	
a.	X	Descriptive Title of the Invention	
a. b.	X X	Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable)	
a. b. c. d.	X X O	Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	
a. b. c. d.		Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix Background of the Invention	
a. b. c. d. e.		Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix Background of the Invention Brief Summary of the Invention	
a. b. c. d.		Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed)	
a. b. c. d. e.		Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix Background of the Invention Brief Summary of the Invention	
a. b. c. d. e. f.		Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed)	

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 16833

Total Pages in this Submission 4

· 3.		Drawing(s) (when necessary as prescribed by 35 USC 113)
	a.	☐ Formal Number of Sheets
	b.	☐ Informal Number of Sheets
4.	X	Oath or Declaration
	a.	☐ Newly executed (original or copy) ☐ Unexecuted
•.	b.	☑ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
	C,	☐ With Power of Attorney ☐ Without Power of Attorney
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.	×	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7.		Application Data Sheet (See 37 CFR 1.76)
· 8.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
ti-	a.	☐ Computer Readable Form (CRF)
	b.	□ Specification Sequence Listing on:
		i. CD-ROM or CD-R (2 copies); or
	•	ii. 🔲 Paper
	c.	☐ Statement(s) Verifying Identical Paper and Computer Readable Copy
		Accompanying Application Parts
9.		Assignment Papers (cover sheet & document(s))
10.	Ö	37 CFR 3.73(B) Statement (when there is an assignee)
11.		English Translation Document (if applicable)
12.		Information Disclosure Statement/PTO-1449 Copies of IDS Citations
13.		Preliminary Amendment
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	×	Certificate of Mailing
		☐ First Class ☒ Express Mail (Specify Label No.): EV 185861686US

Application El ments (Continued)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 16833

Total Pages in this Submission

Accompanying Application Parts (Continued)

7.	×	Additional Enclosures	s (please identify below):	· · · · · · · · · · · · · · · · · · ·			·
4	ľ	Assignee Name:	Finnfeeds Finland Oy				
•		Assignee Address:	Espoo, Finland	· · · · · · · · · · · · · · · · · · ·			
	•	÷				•	
	. 5		•		•		
ŧ							•

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **16833**

Total Pages in this Submission 4

(19) Correspondence Address Customer Number: 23389

Fee Calculation and Transmittal

CLAIMS AS FILED #Filed #Allowed Rate For #Extra Fee 17 - 20 = 0 \$18.00 **Total Claims** 3 0 \$84.00 Indep. Claims - 3 = Multiple Dependent Claims (check if applicable)

BASIC FEE \$750.00
OTHER FEE (specify purpose)
\$0.00
TOTAL FILING FEE \$750.00

Δ	A check in the amount of	\$750.00	to cover the filing fee is enclosed	•	
X	The Director is hereby autho	rized to charg	ge and credit Deposit Account No.	1	9-1013/SSMP
	as described below.				
	Charge the amount	of	as filing fee.		
	Credit any overpaym	ent.			

□ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1,17.

Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Signature

Dated: July 11, 2003

Leopold Presser, Esq. Registration No.: 19,827

LP/rjl cc: \$0.00

\$0.00

\$0.00

CERTIFICATE OF N Applicant(s): Anneli Torr	MAILING BY "EXPRE r nen, et al.	ESS MAIL" (37 CFR 1.10)	Docket No. 16833
Serial No. Unassigned	Filing Date Herewith	3:	Examiner Unassigned	Group Art Unit Unassigned
Invention: USE OF BET	AINE IN FUNCTIONAL P	RODUCTS HA	VING BLOOD PRESSI	URE LOWERING EFFECT
	••			
			74E	
I hereby certify that the	following correspondence:			-
New Application				
, *			*	
	the United States Postal S		s Mail Post Office to A	ddressee" service under 37 kandria, VA 22313-1450 on
	July 11, 2003	÷ 10		
	(Date)	x	Leopold Press	J.
			r Printed Name	HM
* *		(S	EV 1815861686	aus

Note: Each paper must have its own certificate of mailing.

ERTIFICATE OF Molicant(s): Anneli T	IAILING BY "EXPRESS nen, et al.	5 MAIL" (37 CFR 1.10)	Docket No. 16833
Serial No. Unassigned	Filing Date Herewith	Examiner Unassigned	Group Art Unit Unassigned
ention: USE OF BETA	AINE IN FUNCTIONAL PRO	DUCTS HAVING BLOOD PRESS	SURE LOWERING EFFEC
hereby certify that the t	following correspondence:	-	
New Application	(Identify typ	e of correspondence)	
s being deposited with	the United States Postal Serv	rice "Express Mail Post Office to er for Patents, P.O. Box 1450, Ale	
being deposited with	the United States Postal Service addressed to: Commission	rice "Express Mail Post Office to er for Patents, P.O. Box 1450, Ale	exandria, VA 22313-1450
being deposited with	the United States Postal Serve addressed to: Commissione July 11, 2003	rice "Express Mail Post Office to er for Patents, P.O. Box 1450, Ale Leopold Pres	sure 86US